SOUTH SAN FRANCISCO, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT) today announced positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with ...
Thursday, Silo Pharma Inc (NASDAQ:SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The ...
- Zilebesiran Met Primary Endpoint Demonstrating Greater than 15 mmHg Reduction of Systolic Blood Pressure at Three Months of Treatment Compared to Placebo at Two Highest Single Doses Evaluated - - ...
(RTTNews) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Thursday positive topline results from the KARDIA-1 Phase 2 study of zilebesiran. zilebesiran is an investigational ...
SEATTLE, Aug. 20, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast ...
Vaxart Inc VXRT announced topline data from the dose-ranging Phase 2 trial of its oral pill bivalent norovirus vaccine candidate. Norovirus causes acute viral gastroenteritis. There are no approved ...
French medicines agency ANSM and Ethics Committee authorize the dose-ranging study investigating two doses of candidate product for the treatment of ND4-LHON. Approval of the study protocol will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results